Technical / White Paper
Smart strategies for sustained release matrix tablets: Compritol® 888 ATO
This white paper gives an overview of how Compritol® 888 ATO provides clinically relevant sustained drug release profiles along with biopharmaceutical, formulation and manufacturing advantages.
We provide an insight on formulation critical attributes, how Compritol® can be used in a range of production processes and how process flexibility can leverage formulation simplification or provide approaches for overcoming formulation challenges or alternatively, enable the development of innovative drug delivery systems.
At Gattefossé we aim to share our knowledge to help formulators use lipid excipients to their best advantage.
